



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: August 28, 2009

To: Primary Clinical Research Associates

From: Janis Wobschall
Research Protocol Specialist

Re: N0779, Phase II Study of Vorinostat (SAHA) in Combination with Bortezomib
PS-341) in Patients with Recurrent Glioblastoma Multiforme

The Pre-Registration Eligibility Checklist has been updated as follows:

| Form Title | Brief Description of Edit |
|---|--|
| Pre-Registration (Step 1) Eligibility Checklist | <p>Addendum 4, dated February 20, 2009 required IRB approval prior to enrollment, all sites should have submitted Addendum 4 through their IRB, and therefore, the following has been removed from page 1 of 2:</p> <ul style="list-style-type: none">• Addendum 4 dated February 20, 2009 IRB approved? ___ Yes. If Yes, Addendum 4 approval date (<i>mm/dd/yyyy</i>) ___/___/___ — ___ No. If No, End form, Addendum 4 IRB approval required. |

If you have any questions, please feel free to contact me.

Enclosure